Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France

被引:311
作者
Soufir, N
Avril, MF
Chompret, A
Demenais, F
Bombled, J
Spatz, A
Stoppa-Lyonnet, D
Bénard, J
Bressac-de Paillerets, B
机构
[1] Inst Gustave Roussy, Unite Marqueurs Genet Canc, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Serv Dermatol, F-94805 Villejuif, France
[3] Hop St Louis, INSERM U358, F-75010 Paris, France
[4] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France
[5] Inst Curie, Unite Genet Oncol, F-75005 Paris, France
关键词
D O I
10.1093/hmg/7.2.209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations in the p16 and CDK4 genes have been reported in a subset of melanoma pedigrees, but their prevalence is not well known, We searched for such germline mutations in 48 French melanoma-prone families selected according to two major criteria: families with at least three affected members (n = 20) or families with two affected members, one of them affected before the age of 50 (n = 28), and one additional minor criterion, Sixteen different p16 germline mutations were found in 21 families, while one germline mutation, Arg24His, was detected in the CDK4 gene, The frequency of p16 gene mutation in our sample (44%) is among the highest rates yet reported and the CDK4 mutation is the second mutation detected in this gene worldwide, In summary, our results show frequent involvement of the p16 gene in familial melanoma and confirm the role of the CDK4 gene as a melanoma-predisposing gene.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 64 条
[1]   The Queensland Familial Melanoma Project: Study design and characteristics of participants [J].
Aitken, JF ;
Green, AC ;
MacLennan, R ;
Martin, NG .
MELANOMA RESEARCH, 1996, 6 (02) :155-165
[2]   SYSTEMIC CANCER AND THE FAMMM SYNDROME [J].
BERGMAN, W ;
WATSON, P ;
DEJONG, J ;
LYNCH, HT ;
FUSARO, RM .
BRITISH JOURNAL OF CANCER, 1990, 61 (06) :932-936
[3]  
Borg A, 1996, CANCER RES, V56, P2497
[4]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[5]   ASSIGNMENT OF A LOCUS FOR FAMILIAL MELANOMA, MLM, TO CHROMOSOME-9P13-P22 [J].
CANNONALBRIGHT, LA ;
GOLDGAR, DE ;
MEYER, LJ ;
LEWIS, CM ;
ANDERSON, DE ;
FOUNTAIN, JW ;
HEGI, ME ;
WISEMAN, RW ;
PETTY, EM ;
BALE, AE ;
OLOPADE, OI ;
DIAZ, MO ;
KWIATKOWSKI, DJ ;
PIEPKORN, MW ;
ZONE, JJ ;
SKOLNICK, MH .
SCIENCE, 1992, 258 (5085) :1148-1152
[6]   GENETIC ASPECTS OF MALIGNANT MELANOMA [J].
CAWLEY, EP .
AMA ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1952, 65 (04) :440-450
[7]  
DEVATHAIRE F, 1996, ESTIMATION INCIDENCE
[8]   Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16(CDKN2/INK4A) [J].
Fahraeus, R ;
Paramio, JM ;
Ball, KL ;
Lain, S ;
Lane, DP .
CURRENT BIOLOGY, 1996, 6 (01) :84-91
[9]   Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population [J].
FitzGerald, MG ;
Harkin, DP ;
SilvaArrieta, S ;
MacDonald, DJ ;
Lucchina, LC ;
Unsal, H ;
ONeill, E ;
Koh, J ;
Finkelstein, DM ;
Isselbacher, KJ ;
Sober, AJ ;
Haber, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8541-8545
[10]  
Flores JF, 1996, CANCER RES, V56, P5023